Literature DB >> 20447128

Aciclovir-resistant herpes keratitis.

Keat Choong1, Nathan J Walker, Andrew Jg Apel, Michael Whitby.   

Abstract

Herpes simplex virus (HSV) keratitis is a common cause of ocular morbidity. Resistance to aciclovir is probably under recognized. We describe three cases of aciclovir-resistant herpes simplex virus keratitis treated with systemic foscarnet and present a review of the pharmacological options available to manage this condition.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20447128     DOI： 10.1111/j.1442-9071.2010.02209.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN： 1442-6404            Impact factor:   4.207


  18 in total

Review 1.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

2.  Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): transporter recognition, tissue stability and antiviral activity.

Authors:  Aswani Dutt Vadlapudi; Ramya Krishna Vadlapatla; Ravinder Earla; Suman Sirimulla; Jake Brain Bailey; Dhananjay Pal; Ashim K Mitra
Journal:  Pharm Res       Date:  2013-05-09       Impact factor: 4.200

3.  Activation of checkpoint kinase 2 is critical for herpes simplex virus type 1 replication in corneal epithelium.

Authors:  Oleg Alekseev; Vladimir Limonnik; Kelly Donovan; Jane Azizkhan-Clifford
Journal:  Ophthalmic Res       Date:  2014-12-19       Impact factor: 2.892

Review 4.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

5.  Nonthermal Dielectric Barrier Discharge (DBD) Plasma Suppresses Herpes Simplex Virus Type 1 (HSV-1) Replication in Corneal Epithelium.

Authors:  Oleg Alekseev; Kelly Donovan; Vladimir Limonnik; Jane Azizkhan-Clifford
Journal:  Transl Vis Sci Technol       Date:  2014-03-27       Impact factor: 3.283

6.  Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin.

Authors:  V M Quintana; N I Torres; M B Wachsman; P J Sinko; V Castilla; M Chikindas
Journal:  J Appl Microbiol       Date:  2014-08-23       Impact factor: 3.772

7.  Safety, formulation, and in vitro antiviral activity of the antimicrobial peptide subtilosin against herpes simplex virus type 1.

Authors:  Nicolás I Torres; Katia Sutyak Noll; Shiqi Xu; Ji Li; Qingrong Huang; Patrick J Sinko; Mónica B Wachsman; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2013-03-01       Impact factor: 4.609

8.  Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient.

Authors:  Dongli Pan; Stephen B Kaye; Mark Hopkins; Ruaidhri Kirwan; Ian J Hart; Donald M Coen
Journal:  J Infect Dis       Date:  2013-08-14       Impact factor: 5.226

9.  Inhibition of ataxia telangiectasia mutated (ATM) kinase suppresses herpes simplex virus type 1 (HSV-1) keratitis.

Authors:  Oleg Alekseev; Kelly Donovan; Jane Azizkhan-Clifford
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-03       Impact factor: 4.799

10.  Herpes Simplex Virus-1 infection in human primary corneal epithelial cells is blocked by a stapled peptide that targets processive DNA synthesis.

Authors:  Hancheng Guan; Manunya Nuth; Vivian Lee; Chenyan Lin; Claire H Mitchell; Wennan Lu; Richard W Scott; Michael H Parker; John L Kulp; Allen B Reitz; Robert P Ricciardi
Journal:  Ocul Surf       Date:  2020-11-06       Impact factor: 5.033
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.